Psychopharmacology bulletin最新文献

{"title":"A Journey Through Suicidality: Recurrent Attempts, Method Switching, and Psychiatric Diagnostic Challenges.","authors":"Ramya Das, A Ramakrishna Shabaraya, Mithun S Acharya, Aishwarya Bhat, K G Guruprasad, Pooja Gopal Poojari","doi":"10.64719/pb.16626","DOIUrl":"https://doi.org/10.64719/pb.16626","url":null,"abstract":"","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"56 2","pages":"206-209"},"PeriodicalIF":0.0,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12976943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychopharmacotherapy of Alzheimer's Disease-What Do We Have at Hand?","authors":"Ahmed Naguy, Saxby Pridmore, Anubhuti Singh, Awadhesh Solanki","doi":"10.64719/pb.16605","DOIUrl":"10.64719/pb.16605","url":null,"abstract":"<p><p>~ Alzheimer's disease (AD) is a devastating relentlessly progressive illness for which currently there is no definitive curative treatment. The mainstay of treatment remains symptomatic, though. Psychopharmacotherapy is only part of a multi-pronged package of care involving caregivers. Herein, authors would shed light on the main pharmacological options at hand.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"56 2","pages":"170-175"},"PeriodicalIF":0.0,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12976949/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Asenapine in Bipolar Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","authors":"Muneeb Ahmad Muneer, Hafsa, Umair Ahmed, Abdullah Mahmood, Moneeba Khalid, Zain Ali, Warda Fatima Shafee, Suboor Ali Khan, Hanana Nasir, Muhammad Khubair Farrukh, Ume Khansa, Hafsa Arshad Azam Raja, Syed Tehseen Haider","doi":"10.64719/pb.16572","DOIUrl":"10.64719/pb.16572","url":null,"abstract":"<p><strong>Objective: </strong>To provide an updated evaluation of the efficacy and safety of asenapine in bipolar disorder using evidence from randomized controlled trials.</p><p><strong>Methods: </strong>An updated systematic review and pairwise meta-analysis was conducted in accordance with PRISMA guidelines. PubMed, Embase, Scopus, and ClinicalTrials.gov were searched from inception to October 2025. Randomized controlled trials comparing asenapine with placebo were included. The primary outcome was change from baseline in Young Mania Rating Scale (YMRS) scores. Secondary outcomes included Clinical Global Impressions-Bipolar Severity (CGI-BP-S) overall and mania scores, Montgomery-Åsberg Depression Rating Scale (MADRS) scores, and incidence of adverse events. Random-effects models with restricted maximum-likelihood estimation and Hartung-Knapp adjustment were applied.</p><p><strong>Results: </strong>Five trials comprising 1,593 participants were included. Asenapine significantly reduced manic symptoms compared with placebo (YMRS mean difference -4.00, 95% CI -5.55 to -2.45). Significant improvements were observed in CGI-BP-S overall severity (-0.51, 95% CI -0.78 to -0.24) and mania scores (-0.47, 95% CI -0.77 to -0.16). modest improvement was observed in MADRS scores (-1.38, 95% CI -2.52 to -0.24). Adverse events were more frequent with asenapine.</p><p><strong>Conclusion: </strong>Asenapine is an effective short-term treatment for acute mania in bipolar disorder, with tolerability considerations.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"56 2","pages":"8-28"},"PeriodicalIF":0.0,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12976958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Series: Simultaneous Use of Long-Acting Injectable Antipsychotics and Vivitrol or Long-Acting Buprenorphine in Dual Diagnosis Patients with Bipolar Disorder and Substance Use Disorders.","authors":"Adam Zavodnick","doi":"10.64719/pb.16608","DOIUrl":"10.64719/pb.16608","url":null,"abstract":"<p><strong>Background: </strong>Co-occurring substance use disorders and bipolar disorder present treatment challenges including poor medication adherence, increased relapse rates, and complex symptom interactions. This case series evaluates the feasibility and outcomes of concurrent long-acting injectable (LAI) antipsychotics with LAI naltrexone (Vivitrol) or buprenorphine (Sublocade).</p><p><strong>Methods: </strong>Retrospective chart review of patients receiving dual LAI therapy at an addiction psychiatry clinic from January 2016 through December 2020. Inclusion criteria: adults ⩾ 18 years receiving concurrent LAI antipsychotic plus LAI addiction medication for ⩾ 3 months. All data were de-identified in accordance with HIPAA Safe Harbor standards and confirmed by Department. Patient consent was obtained. Per Northwell Health Institutional Review Board policy, approval for case series with fewer than 4 patients was not required.</p><p><strong>Results: </strong>Three patients with bipolar I disorder and polysubstance use disorders (opioids, cocaine, benzodiazepines) were identified. Medication combinations included paliperidone palmitate with Sublocade (n = 2) and aripiprazole lauroxil with Sublocade (n = 1). All three patients demonstrated clinical improvement: one achieved excellent response with sustained remission of both psychiatric and substance use symptoms; two showed partial response with reduced opioid use (though cocaine use remained problematic in one patient). No severe adverse effects occurred. All patients received adjunctive acceptance and commitment therapy.</p><p><strong>Conclusions: </strong>Simultaneous use of LAI antipsychotics with Vivitrol or Sublocade demonstrated feasibility and utility, with all patients showing benefit. This combination approach may be particularly valuable for patients with poor medication adherence. Preliminary findings support the need for controlled research to establish optimal patient selection criteria, medication combinations, and predictors of treatment response.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"56 2","pages":"176-180"},"PeriodicalIF":0.0,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12976946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Agomelatine-Induced Subjective Double Delusion in Adolescent Bipolar Disorder.","authors":"Yiğit Özaydın, Birsen Şentürk Pilan, Tezan Bildik","doi":"10.64719/pb.16611","DOIUrl":"10.64719/pb.16611","url":null,"abstract":"<p><strong>Background: </strong>Delusional misidentification syndromes are rare psychiatric conditions, and subjective double delusion is particularly uncommon in adolescents. Agomelatine, an antidepressant with melatonergic and serotonergic properties, has limited evidence in pediatric populations and may trigger mood instability in vulnerable individuals.</p><p><strong>Case presentation: </strong>We report the case of a 17-year-old male with a history of depressive symptoms who developed a manic episode with psychotic features shortly after initiating agomelatine. The clinical picture was dominated by a subjective double delusion, in which the patient believed an identical double existed and conspired against him. Following discontinuation of agomelatine and initiation of olanzapine, significant clinical improvement was observed within three weeks. Symptom reduction was confirmed with standardized rating scales.</p><p><strong>Conclusion: </strong>This case highlights the importance of cautious antidepressant use in adolescents at risk for bipolar disorder. Clinicians should closely monitor for emerging manic or psychotic symptoms and provide timely interventions to prevent serious complications.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"56 2","pages":"181-186"},"PeriodicalIF":0.0,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12976947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Effectiveness of Naltrexone Formulations in Alcohol Use Disorder: An Updated Meta-Analysis.","authors":"Nicolas A Nunez, Hossam M Ali, Leslie Hassett, Balwinder Singh","doi":"10.64719/pb.16596","DOIUrl":"10.64719/pb.16596","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to synthesize and provide an updated meta-analysis of the current data on extended-release naltrexone (XR-NTX) and oral naltrexone (NTX) for alcohol use disorder (AUD).</p><p><strong>Methods: </strong>A comprehensive database search was conducted and updated on October 1, 2025. This meta-analysis encompassed randomized controlled trials (RCTs) and observational studies that compared XR-NTX and oral NTX in adults with AUD. Included studies reported outcomes on treatment persistence and healthcare utilization, specifically ED visits and inpatient hospitalizations during follow-up. Odds ratios (ORs) were computed using the Mantel-Haenszel random-effects model.</p><p><strong>Results: </strong>Out of 101 studies screened, seven studies (N = 42,268; n = 2,103 for XR-NTX, n = 40,165 for NTX) met the inclusion criteria for the meta-analysis. Overall, treatment persistence was significantly higher with XR-NTX compared with oral NTX (OR = 1.94 [95% CI, 1.22-3.10]), with benefits observed at both three months (pooled OR = 2.24 [95% CI, 1.14-4.41], p = 0.019) and six months (OR = 1.59 [95% CI, 1.04-2.43], p = 0.032). No significant differences were observed in healthcare utilization, including all-cause ED visits (OR = 1.33 [95% CI, 0.93-1.90]) or all-cause inpatient admissions (OR = 0.84 [95% CI, 0.49-1.43]).</p><p><strong>Conclusion: </strong>This meta-analysis suggests higher treatment persistence among patients with AUD receiving XR-NTX versus oral NTX, underscoring formulation as a key factor in persistence and retention. However, alcohol-related healthcare utilization metrics, including ED visits and hospitalizations, showed no significant between-group differences. Further pragmatic trials accounting for patient preferences, sex-specific outcomes, and barriers to care accessibility are needed.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"56 2","pages":"130-148"},"PeriodicalIF":0.0,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12976952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smoking Status Among Patients Presenting to a Chronic Pain Clinic: A Retrospective Review from a University-Affiliated Pain Clinic.","authors":"Jamal Hasoon, Jacob Ng, John Spikes, Karla Samaniego, Omar Viswanath, Ivan Urits, Christopher L Robinson","doi":"10.64719/pb.16581","DOIUrl":"10.64719/pb.16581","url":null,"abstract":"<p><strong>Background: </strong>Tobacco use is a known contributor to poor health outcomes and may influence chronic pain severity and prognosis. Understanding smoking patterns among patients presenting to a chronic pain clinic provides valuable insight into patient risk profiles and opportunities for targeted interventions.</p><p><strong>Methods: </strong>We conducted a retrospective review of smoking status among all patients presenting to a university-affiliated chronic pain clinic between January 1, 2022, and June 30, 2024. Smoking status was taken from intake documentation within the electronic medical record. Patients were classified based on reported status at the time of intake.</p><p><strong>Results: </strong>A total of 3,191 patients were included in the analysis. Of these, 2,056 (64.4%) reported never smoking, 749 (23.5%) reported being former smokers, and 234 (7.3%) reported smoking every day. An additional 122 patients (3.8%) reported smoking on some days. Other classifications included 1 (<0.1%) reporting passive smoke exposure, 12 (0.4%) selecting \"none of the above,\" and 17 (0.5%) with smoking status not assessed or unknown.</p><p><strong>Conclusion: </strong>In this chronic pain clinic population, nearly one-third of patients reported current or former smoking status, with the majority being never smokers. Given the established links between smoking and adverse pain-related outcomes, these findings support the integration of smoking cessation counseling and tobacco risk reduction strategies into chronic pain management.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"56 2","pages":"58-67"},"PeriodicalIF":0.0,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12976950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and Risk Factors of Clozapine-Induced Neutropenia among Patients with Schizophrenia in Taif, Saudi Arabia.","authors":"Ahmed Salem Altowairqi, Anas Ibn Auf, Saeed Saeed Alghamdi","doi":"10.64719/pb.16593","DOIUrl":"10.64719/pb.16593","url":null,"abstract":"<p><strong>Background: </strong>Clozapine remains the most effective antipsychotic medication for treatment-resistant schizophrenia, but its use is limited by the risk of hematological side effects, particularly neutropenia. The present study aimed to determine the incidence and potential risk factors of neutropenia among patients receiving clozapine at a mental health hospital in Taif, Saudi Arabia.</p><p><strong>Method: </strong>A retrospective analytical study was conducted using electronic medical records of Saudi adult patients diagnosed with schizophrenia initiated on clozapine during one-year. Demographic and clinical data were collected, including age, gender, presence of chronic medical conditions, starting dose, and treatment duration. The absolute neutrophil count (ANC) was used as the dependent variable. Statistical analysis was performed using the chi-square test, and results with p < 0.05 were considered significant.</p><p><strong>Results: </strong>Eighty-nine patients were included (70 males and 19 females). Twenty participants (22.5%) developed neutropenia during clozapine therapy; most cases were mild. Neutropenia was less frequent among patients older than 30 years (20%) compared with younger patients (31.6%), but this difference was not statistically significant (p = 0.28). No significant associations were observed between neutropenia and gender, presence of chronic diseases, or starting dose. However, a significant relationship was found between treatment duration and the development of neutropenia (p < 0.001).</p><p><strong>Conclusion: </strong>The incidence of clozapine-induced neutropenia among patients in this Saudi sample was higher than rates reported internationally, emphasizing the need for close hematological monitoring during the first months of therapy. Awareness among psychiatrists, pharmacists, and healthcare teams should be reinforced to ensure early detection and appropriate management.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"56 2","pages":"122-129"},"PeriodicalIF":0.0,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12976957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-Catatonic Mutism as a Presentation of Psychosis: A Case Study.","authors":"Mridul Sarangal, Michael P Greenage","doi":"10.64719/pb.16623","DOIUrl":"10.64719/pb.16623","url":null,"abstract":"<p><strong>Objective: </strong>To describe a rare case of non-catatonic mutism as the primary presentation of psychosis in a patient with complex comorbidities, highlighting diagnostic differentiation and antipsychotic response.</p><p><strong>Methods: </strong>Case report of a 47-year-old female with bipolar II disorder, post-traumatic stress disorder, polysubstance use, and homelessness presenting with intermittent mutism. Diagnostic evaluation included clinical history, Bush-Francis Catatonia Rating Scale (BFCRS), and exclusion of alternative etiologies. Treatment involved antipsychotics with legal authorization.</p><p><strong>Results: </strong>BFCRS score of 3 ruled out catatonia. Mutism resolved with haloperidol 4 mg daily after initial olanzapine failure, with no overt psychotic symptoms. Integrated care addressed social determinants.</p><p><strong>Conclusions: </strong>Non-catatonic mutism may represent isolated psychosis, responsive to antipsychotics. Systematic evaluation is crucial in atypical presentations with psychosocial complexity.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"56 2","pages":"203-205"},"PeriodicalIF":0.0,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12976944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Retrospective Study of Mood and Anxiety Disorders Management Profile (MooD-MaP) of Patients Admitted at the Makati Medical Center from 2014-2017.","authors":"Carmina Charmaine G Bernardo, Elaine Angela O Leynes, Sophia Grace Benosa, Lorraine Freyja Linsangan, Robin Myan Dantes, Vichka Claire Sison, Ormalyn Bayting","doi":"10.64719/pb.16584","DOIUrl":"10.64719/pb.16584","url":null,"abstract":"<p><p>Mood and anxiety disorders are leading causes of psychiatric hospitalization. However, data on real-world inpatient psychopharmacologic practices in the Philippines are limited. This study aims to describe the clinical characteristics and psychotropic medication prescribing patterns among inpatients with mood and anxiety disorders at a tertiary private hospital in the Philippines. This retrospective descriptive study reviewed medical records of patients admitted to the Section of Psychiatry at Makati Medical Center from January 1, 2014, to December 31, 2017. Patients with a primary DSM-5 diagnosis of bipolar disorder (BD), major depressive disorder (MDD), or anxiety disorder (AD) were included. Demographic and clinical characteristics, suicidality, and psychotropic prescribing patterns were summarized using descriptive statistics. A total of 705 patients were included: 350 (49.6%) with BD, 301 (42.7%) with MDD, and 54 (7.7%) with AD. Depressed mood was the most common presentation at admission (58.6%), and 72.2% of patients were euthymic at discharge. Suicide attempts were documented in more than half of patients with available data. Valproate, quetiapine, clonazepam, and aripiprazole were the most frequently prescribed medications for BD. In MDD, clonazepam, escitalopram, quetiapine, and aripiprazole predominated, while clonazepam and selective serotonin reuptake inhibitors were most commonly used in AD. Polypharmacy was frequent across diagnostic groups. Psychopharmacologic management of hospitalized patients with mood and anxiety disorders in this Philippine tertiary center largely aligns with international practice. High rates of polypharmacy and suicidality underscore the need for optimized, evidence-based prescribing and longitudinal outcome studies.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"56 2","pages":"68-93"},"PeriodicalIF":0.0,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12976951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}